2021 ASH Annual Meeting: Focus on MDS
Pivotal trials that supported Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell ...
Treatment with the investigational injectable hepcidin mimetic rusfertide effectively controlled levels of hematocrit ...
According to results from a phase I/II study, more than 90% of older and high-risk patients with newly diagnosed acute ...
In in vitro and in vivo preclinical models, the combination of magrolimab with venetoclax plus azacitidine increased ...
Based on analysis of data from the ACTIVATE and ACTIVATE-T studies and their associated long-term extension (LTE) ...
A study presented at the American Society of Hematology’s 2021 Annual Meeting & Exposition found that the presence ...
For older and high-risk patients with newly diagnosed acute myeloid leukemia (AML), the treatment combination of ...
The combination of eltrombopag and lenalidomide is effective and safe at treating certain patients with myelodysplastic ...
According to findings from a survey study presented at the 2021 ASH Annual Meeting, blood transfusion services are ...
Sabatolimab, an immunotherapeutic therapy targeting TIM-3 on immune and myeloid cells, was well-tolerated and led to ...
As a plenary abstract at the 2021 ASH Annual Meeting, Alba Rodriguez-Meira, PhD-c, of MRC Weatherall Institute of ...
According to a phase II study presented at the 2021 American Society of Hematology Annual Meeting, ivosidenib, a ...
Prescribing chemotherapy is not a universal practice of advanced practice providers (APPs) in the oncology community, ...
Findings from the REGARDS trial reveal that peripheral blood cytopenias may be associated with a higher risk of ...
According to data presented at the 2021 American Society of Hematology Annual Meeting, an updated International ...
Advertisement
Advertisement
